Xavier Thomas

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome
    Nabaz Jaff
    Service d Hematologie, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    Leuk Res 31:67-73. 2007
  2. pmc Promyelocytic sarcoma of the sternum: a case report and review of the literature
    Xavier Thomas
    Department of Hematology, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Korean J Hematol 46:52-6. 2011
  3. pmc Tipifarnib in the treatment of acute myeloid leukemia
    Xavier Thomas
    Hematology, Edouard Herriot Hospital, Lyon, France
    Biologics 1:415-24. 2007
  4. doi A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
    Xavier G Thomas
    Department of Haematology, Lyon Sud Hospital, Lyon, France Electronic address
    Clin Lymphoma Myeloma Leuk 14:68-72. 2014
  5. doi DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences
    Xavier Thomas
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d Hematologie Clinique, Pierre Benite, France
    Expert Opin Drug Discov 7:1039-51. 2012
  6. doi Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
    Xavier Thomas
    Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Leuk Res 36:1112-8. 2012
  7. doi Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
    Xavier Thomas
    Hospices Civils de Lyon, Lyon Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat 1G, 69495 Pierre Benite, France
    Expert Opin Investig Drugs 21:871-8. 2012
  8. pmc A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
    Jorge Sierra
    Division of Clinical Hematology, Hospital de Santa Creu i Sant Pau, Barcelona, Spain
    BMC Cancer 8:195. 2008
  9. ncbi Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study
    Xavier Thomas
    Department of Hematology, Edouard Herriot Hospital, Lyon, France
    Cancer 116:1725-32. 2010
  10. ncbi Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 69437, Lyon Cedex 03, France
    Hematol J 5:384-94. 2004

Detail Information

Publications118 found, 100 shown here

  1. ncbi Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome
    Nabaz Jaff
    Service d Hematologie, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    Leuk Res 31:67-73. 2007
    ..0002). Trisomy 8 in addition to favorable karyotype maintained a good clinical outcome, while trisomy 8 in addition to unfavorable cytogenetics showed the worst prognosis...
  2. pmc Promyelocytic sarcoma of the sternum: a case report and review of the literature
    Xavier Thomas
    Department of Hematology, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Korean J Hematol 46:52-6. 2011
    ..The patient was treated by surgery followed by chemotherapy plus all-trans retinoic acid therapy and local radiotherapy...
  3. pmc Tipifarnib in the treatment of acute myeloid leukemia
    Xavier Thomas
    Hematology, Edouard Herriot Hospital, Lyon, France
    Biologics 1:415-24. 2007
    ..Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing...
  4. doi A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
    Xavier G Thomas
    Department of Haematology, Lyon Sud Hospital, Lyon, France Electronic address
    Clin Lymphoma Myeloma Leuk 14:68-72. 2014
    ..Decitabine use demonstrated greater response rates (P = .001) and OS data favored decitabine...
  5. doi DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences
    Xavier Thomas
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d Hematologie Clinique, Pierre Benite, France
    Expert Opin Drug Discov 7:1039-51. 2012
    ....
  6. doi Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
    Xavier Thomas
    Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Leuk Res 36:1112-8. 2012
    ..We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease...
  7. doi Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
    Xavier Thomas
    Hospices Civils de Lyon, Lyon Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat 1G, 69495 Pierre Benite, France
    Expert Opin Investig Drugs 21:871-8. 2012
    ..Preclinical data indicate activity against B-cell tumors and early results from clinical trials indicate activity against B-cell lineage acute lymphoblastic leukemia (ALL)...
  8. pmc A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
    Jorge Sierra
    Division of Clinical Hematology, Hospital de Santa Creu i Sant Pau, Barcelona, Spain
    BMC Cancer 8:195. 2008
    ....
  9. ncbi Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study
    Xavier Thomas
    Department of Hematology, Edouard Herriot Hospital, Lyon, France
    Cancer 116:1725-32. 2010
    ..In a first report, we have shown that priming with granulocyte-macrophage colony-stimulating factor (GM-CSF) may enhance complete remission (CR) rate and event-free survival (EFS) in younger adults with acute myeloid leukemia (AML)...
  10. ncbi Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 69437, Lyon Cedex 03, France
    Hematol J 5:384-94. 2004
    ..04). There were no significant differences between the three groups in terms of disease-free survival...
  11. ncbi Cigarette smoking and acute leukemia
    Xavier Thomas
    Leukemia Unit, Hematology Department, Edouard Herriot Hospital, Lyon, France
    Leuk Lymphoma 45:1103-9. 2004
    ..The data reported in this review are derived from the medical literature and from the experience of the authors...
  12. ncbi Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 69437, Lyon Cedex 03, France
    J Clin Oncol 22:4075-86. 2004
    ..We analyzed the benefits of a risk-adapted postremission strategy in adult lymphoblastic leukemia (ALL), and re-evaluated stem-cell transplantation (SCT) for high-risk ALL...
  13. ncbi Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
    X Thomas
    Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Leuk Lymphoma 46:1007-16. 2005
    ....
  14. ncbi Chemotherapy of acute leukemia in adults
    Xavier Thomas
    Hopital Edouard Herriot, Service d Hematologie, Leukemia Unit, Department of Hematology, 69437 Lyon Cedex 03, France
    Expert Opin Pharmacother 10:221-37. 2009
    ..General therapeutic options for adult patients with acute leukemia are reviewed and specific new treatment strategies are described...
  15. ncbi New emerging applications of molgramostim in acute myeloid leukaemia
    Xavier Thomas
    Edouard Herriot Hospital, Department of Haematology, Hospices Civils de Lyon, 69437, Lyon Cedex 03, France
    Expert Opin Drug Metab Toxicol 4:795-806. 2008
    ....
  16. ncbi Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia
    Xavier Thomas
    Département d ématologie, Hopital Edouard Herriot, Lyon Cedex 03, France
    Leuk Res 29:1049-58. 2005
    ....
  17. ncbi [Acute lymphoblastic leukemia in elderly: prognosis and treatment]
    Xavier Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, 69437 Lyon
    Bull Cancer 91:713-20. 2004
    ..New therapeutic approaches are warranted to improve the outcome in this age group of ALL patients...
  18. doi [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]
    X Thomas
    Hopital Edouard Herriot, Lyon, France
    Bull Cancer 97:1105-17. 2010
    ..Advantages of these therapeutic alternatives to native L-asparaginase and their results as part of preliminary clinical trials in adults have been outlined in this review...
  19. ncbi Heat shock proteins and acute leukemias
    Xavier Thomas
    Departement d Hematologie, Hopital Edouard Herriot, Lyon, France
    Hematology 10:225-35. 2005
    ....
  20. ncbi Emerging drugs for adult acute lymphoblastic leukaemia
    Xavier Thomas
    Department of Hematology, Edouard Herriot Hospital, Lyon, France
    Expert Opin Emerg Drugs 10:591-617. 2005
    ..With a better understanding of the disease, more target-specific therapies could be designed. The aim of this review is to highlight new pharmacotherapies and those emerging drug treatments for patients with adult ALL...
  21. ncbi Clofarabine for the treatment of adult acute myeloid leukemia
    Xavier Thomas
    Hematology, Edouard Herriot Hospital, Hospices Civils de Lyon, Place d Arsonval, 69437, Lyon Cedex 03, France
    Future Oncol 5:1197-210. 2009
    ..Current studies are underway to better define the role of clofarabine in younger and elderly patients with AML, and also explore development strategies for an oral formulation...
  22. ncbi Leukemia stem cells and new strategies to overcome resistance to therapy
    Xavier Thomas
    Department of Hematology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
    Curr Stem Cell Res Ther 5:277-86. 2010
    ..New strategies are required that specifically target the malignant stem cell population...
  23. ncbi [Special issues related to the treatment of acute leukemias in women]
    X Thomas
    Hopital Edouard Herriot, Service hématologie, 5, Place d Arsonval, 69437 Lyon, France
    Bull Cancer 97:1011-22. 2010
    ..All these special issues are addressed in this review of the literature...
  24. doi The role of timed sequential chemotherapy in adult acute myelogenous leukemia
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, Lyon Cedex 03, France
    Curr Hematol Malig Rep 3:89-95. 2008
    ..This article reviews the results of important trials in which TSC was used as an induction regimen in de novo, relapsed, or refractory acute myelogenous leukemia or as postremission therapy...
  25. ncbi Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 69437, Lyon Cedex 03, France
    Ann Hematol 84:376-82. 2005
    ..CR proportion was significantly higher in patients with a first CR duration > or =6 months when compared with those from a control trial using standard-dose mitoxantrone (90 vs 70%, p=0.03)...
  26. ncbi [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia]
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 5, place Arsonval, 69437 Lyon Cedex 03
    Bull Cancer 92:227-38. 2005
    ..It is anticipated that these studies will serve to define the optimal roles of FTIs in patients with these hematologic malignancies and provide insight into effective methods by which to combine FTIs with other agents...
  27. doi Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study
    Xavier Thomas
    Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Blood 118:1754-62. 2011
    ..This study demonstrates that TSC did not produce any benefit when used as consolidation therapy in younger adults compared with HDAraC. This trial was registered at www.clinicaltrials.gov as #NCT00880243...
  28. doi Central nervous system involvement in adult acute lymphoblastic leukemia
    Xavier Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, Hospices Civils de Lyon, 69437 Lyon Cedex 03, France
    Hematology 13:293-302. 2008
    ..Leukemic relapse remains a major therapeutic problem and CNS involvement at the time of relapse occurs in 1-15% of cases. Adult ALL with CNS recurrence remains of poor prognosis and is generally associated with a systemic relapse...
  29. ncbi Prognostic factors in adult acute lymphoblastic leukemia
    Xavier Thomas
    Service d Hematologie, Clinique Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France
    Hematology 8:233-42. 2003
    ....
  30. doi [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?]
    Xavier Thomas
    Hopital Edouard Herriot, Hematologie, 5, Place d Arsonval, 69437 Lyon, France
    Bull Cancer 98:761-7. 2011
    ..AP24534 could be the next treatment of choice in hematological malignancies with Philadelphia-positive chromosome, particularly Ph(+) ALL known for its frequent occurrence of T315I mutation...
  31. ncbi [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview]
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Bull Cancer 95:707-15. 2008
    ..Leukemic relapse remains a major therapeutic challenge. Adult ALL with CNS recurrence remains of poor prognosis and is generally associated with a systemic and medullary relapse...
  32. ncbi [Current therapeutic strategies in acute lymphoblastic leukemia in the adult]
    Xavier Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, 69437 Lyon
    Bull Cancer 90:833-50. 2003
    ..New treatment options, needed to be developed to further improve on the therapeutic perspectives for adult patients with ALL, and therapeutic schedules of main cooperative groups are also reviewed...
  33. ncbi [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]
    Xavier Thomas
    Hematologie, Hopital Edouard Herriot, 5, Place d Arsonval, 69437 Lyon
    Bull Cancer 94:871-80. 2007
    ....
  34. ncbi Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia
    Xavier Thomas
    Leukemia Unit, Hematology Department, Edouard Herriot Hospital, Lyon, France
    Hematology 12:15-28. 2007
    ..Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens...
  35. ncbi Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience
    X Thomas
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Am J Hematol 67:73-83. 2001
    ..We conclude that the pejorative overall outcome in elderly ALL points to the need for new therapeutic trials taking into account the specific characteristics of ALL in this age group...
  36. ncbi [Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study]
    X Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon
    Presse Med 29:1745-51. 2000
    ..To test the value of the combination of pefloxacin and vancomycin as gastro-intestinal tract decontamination for the prevention of infections in patients with chemotherapy-induced neutropenia...
  37. ncbi Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia
    X Thomas
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Leuk Res 24:957-63. 2000
    ....
  38. ncbi Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors
    Xavier Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon, France
    Leuk Res 26:909-18. 2002
    ..The persistence of normal residual hematopoiesis and intense leukemic cells mitotic activity were both factors of favorable outcome, while BM fibrosis did not display any prognostic value...
  39. doi Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Xavier Thomas
    Group for Research on Adult Acute Lymphoblastic Leukemia GRAALL, Hematology Department, Edouard Herriot Hospital, Lyon, France
    Leuk Lymphoma 49:1246-54. 2008
    ..New challenges have emerged with respect to induction of resistance to imatinib via ABL mutations. Several novel kinase inhibitors with significantly more potent anti-leukemic activity than imatinib are currently being developed...
  40. ncbi Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study
    Xavier Thomas
    Department of Hematology, Edouard Herriot Hospital, 69437 Lyon Cedex 03, France
    Haematologica 92:389-96. 2007
    ..We evaluate the outcome of this post-remission approach after complete remission (CR) and consolidation in elderly patients included in the EORTC-GIMEMA AML-13 trial...
  41. ncbi [Treatment of acute myeloid leukemias in the adult in relapse]
    Xavier Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, 69437 Lyon
    Bull Cancer 89:795-807. 2002
    ..Molecular monitoring for the PML-RARalpha fusion protein permits prompt intervention for early molecular relapse ultimately improving chances of prolonged remission...
  42. ncbi Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
    X Thomas
    Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Leukemia 21:453-61. 2007
    ..Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML...
  43. ncbi Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?
    Xavier Thomas
    Service d Hematologie Clinique, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Clin Lymphoma Myeloma Leuk 11:342-9. 2011
    ..Identification of valuable factors that can facilitate therapeutic decision-making between intensive chemotherapy and investigational treatment strategies is warranted...
  44. ncbi Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia
    X Thomas
    Department of Hematology, Edouard Herriot Hospital, 69437 Lyon Cedex 03, France
    Ann Hematol 81:504-7. 2002
    ..The questions relating to the pathogenesis of cardiac failure are discussed. We also discuss the prophylactic measures required for such treatment-related side effects...
  45. doi Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, Place d Arsonval, Lyon Cedex 03, France
    Hematology 16:278-83. 2011
    ..It is a potential marker of prognosis in patients with leukemia...
  46. ncbi Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experience
    Anne Sophie Michallet
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Hematology 11:157-64. 2006
    ..Results in adults who experience a relapse after conventional chemotherapy support the use of autologous HSCT as salvage therapy if such patients achieve a subsequent CR...
  47. ncbi Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
    Claude Gardin
    Department of Hematology, Hopital Avicenne, University Paris 13, Bobigny, France
    Blood 109:5129-35. 2007
    ..In conclusion, more prolonged ambulatory treatment should be preferred to intensive chemotherapy as postremission therapy in elderly patients with AML reaching CR after standard intensive remission induction...
  48. ncbi Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study
    Vahid Asnafi
    Department of Hematology, Necker Enfants Malades, Saint Louis, France
    Blood 105:3072-8. 2005
    ..Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs...
  49. ncbi A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule
    Olfa Derbel
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Hematology 15:125-31. 2010
    ....
  50. doi Outcome of older patients with acute myeloid leukemia in first relapse
    Clémentine Sarkozy
    Hematology Department, Hopital Saint Louis, Assistance Publique Hopitaux de Paris AP HP, University Paris 7, 1 avenue Claude Vellefaux, Paris, France
    Am J Hematol 88:758-64. 2013
    ..In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO-containing salvage suggest that GO combination studies should be actively pursued in this setting...
  51. doi Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study
    Aline Tanguy-Schmidt
    Department of Hematology, Service des Maladies du Sang, INSERM U892, PRES LUNAM, University Hospital, Angers, France
    Biol Blood Marrow Transplant 19:150-5. 2013
    ....
  52. ncbi Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
    Lionel Ades
    Assistance Publique Hopitaux de Paris, Hopital Avicenne, Service d Hematologie Clinique, Paris 13 University, Bobigny, France
    J Clin Oncol 24:5703-10. 2006
    ....
  53. ncbi Acute leukemia during pregnancy: a report on 37 patients and a review of the literature
    Youcef Chelghoum
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon, France
    Cancer 104:110-7. 2005
    ..Acute leukemia (AL) requiring cytotoxic treatment occurring during pregnancy poses a very difficult therapeutic dilemma...
  54. ncbi All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial
    Amine Belhabri
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Hematol J 3:49-55. 2002
    ..All trans retinoic acid has shown a remarkable effectiveness in acute promyelocytic leukemia. These results have encouraged studies of treatment with ATRA in other acute myeloid leukemia subtypes...
  55. ncbi Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial
    Herve Dombret
    Department of Hematology, Hopital Saint Louis, Paris, France
    Blood 100:2357-66. 2002
    ..Allogeneic SCT in first CR is the current best treatment option in adults with the disease. New strategies must be tested during early phases of therapy to increase the rate of BCR-ABL(-) remissions...
  56. doi Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older
    Claude Gardin
    Department of Hematology, Hopital Avicenne, AP HP, 125 route de Stalingrad, 93000 Bobigny, France
    J Clin Oncol 31:321-7. 2013
    ..This study aimed to identify factors influencing the long-term outcome in these patients...
  57. doi Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens
    Marie Detrait
    Blood and Marrow Transplant Unit, Department of Hematology, Centre Hospitalier Lyon Sud, University of Lyon, Lyon, France
    Exp Hematol 40:792-9. 2012
    ..We recommend its consideration before allo-HSCT in the donor-recipient selection parameters...
  58. ncbi Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
    Jean Valère Malfuson
    Department of Hematology, Hôpital d Instruction des Armées, Clamart, France
    Haematologica 93:1806-13. 2008
    ..The aim of the present study was to analyze the decisional value of poor risk factors in 416 elderly patients treated in the ALFA-9803 trial in order to derive a decisional index...
  59. ncbi Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study
    Adrienne de Labarthe
    Department of Hematology, Hopital Saint Louis, Paris, France, and Department of Hematology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium
    Blood 109:1408-13. 2007
    ....
  60. doi Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases
    Alice Gougounon
    Service d Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Leuk Res 35:1027-31. 2011
    ..This retrospective analysis points to a somewhat heterogenous group of AML in terms of biological features and outcome, and warrants a larger multicenter study with study in molecular biology to clarify treatment effects further...
  61. ncbi Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience
    Claudiu Plesa
    Leukemia Unit, Edouard Herriot Hospital, Lyon Civil Hospices, Lyon, France
    Cancer 112:572-80. 2008
    ..The impact of initial characteristics on prognosis has been addressed previously in elderly patients; however, very few data are available regarding the prognostic value of immunophenotypic characteristics in this setting...
  62. ncbi Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens
    Anne Sophie Michallet
    Department of Haematology, Edouard Herriot Hospital, Lyon 69437, France
    Br J Haematol 128:676-89. 2005
    ..4% for PMC (P < 0.0001 and P < 0.0001). Multivariate analysis only showed a significant impact of chimaerism status on OS, as well as acute and chronic graft-versus-host disease on EFS, with a trend for conditioning regimen...
  63. ncbi A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
    Stephanie Nguyen
    Department of Hematology, Hopital Saint Louis, Paris, France
    Blood 99:3517-23. 2002
    ..5; intermediate index, 2.5-20; high index, 20 or more). In multivariate analysis, the WBC index was the only prognostic factor for DFS (P =.003), complete remission duration (P =.002), and overall survival (P =.04)...
  64. ncbi Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors
    Emmanuelle Tavernier
    Service d Hematologie Clinique, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    Leuk Res 27:205-14. 2003
    ..All other patients displayed a poor outcome. This suggests their orientation at an earlier time to alternate therapeutic programs based on investigational drugs...
  65. ncbi Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial
    Quoc Hung Le
    Service d Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Cancer 109:2058-67. 2007
    ..In this investigation, the authors attempted to express the results in terms of the proportion of long-term disease-free survivors and in terms of lifetime in patients who developed recurrent disease or died...
  66. ncbi Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
    Sophie Ducastelle
    Service d Hematologie, Pavillon E, CHU, Hopital Edouard Herriot, 5, Place d Arsonval, 69437 Lyon Cedex 03, France
    Haematologica 91:373-6. 2006
    ..The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured...
  67. doi The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication
    Aline Renneville
    Department of Hematology, Hopital Claude Huriez, Lille, France
    Blood 113:5090-3. 2009
    ..7; 95% confidence interval, 1.08-6.7; and 2.9; 95% confidence interval, 1.01-8.2; with P = .034 and .05, for abnormal karyotype and FLT3-ITD, respectively)...
  68. ncbi A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
    Jean Luc Harousseau
    Service d Hematologie, Hotel Dieu, Nantes, France
    Blood 109:5151-6. 2007
    ..The response rate observed in this heavily pretreated group of patients suggests the requirement to enhance the response rate either by combining tipifarnib with other active agents or determining factors that are predictive of response...
  69. doi Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial
    Giovanna Cannas
    Department of Hematology, Hopital Edouard Herriot, Lyon, France
    Leuk Lymphoma 53:1068-76. 2012
    ..Better supportive care strategies may improve overall survival in patients undergoing chemotherapy for acute myeloid leukemia...
  70. ncbi Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia
    Quoc Hung Le
    Service d Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Place d Arsonval, Lyon Cedex 03, France
    Eur J Haematol 77:471-9. 2006
    ..This analysis suggests that predictive factors may be split into tolerance factors and haematological factors. Determination of such factors is crucial to adapt postremission therapeutic strategies in acute lymphoblastic leukaemia...
  71. pmc Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria
    Raphael Itzykson
    Department of Hematology, Hopital Saint Louis, AP HP, EA 3518, University Paris 7, Paris 1, Avenue C Vellefaux, 75010 Paris, France
    Haematologica 96:837-44. 2011
    ..There is no standard post-remission therapy in older patients with acute myeloid leukemia...
  72. pmc Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009
    Marie Christine Nicolle
    Service d Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, France
    Haematologica 96:1685-91. 2011
    ..The study objectives were: 1) to report on invasive aspergillosis patients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis...
  73. pmc Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
    Sebastien Maury
    Service d Hematologie Clinique, CHU Henri Mondor, 51 Av du Mal de Lattre de Tassigny, 94010 Creteil Cedex, France
    Haematologica 95:324-8. 2010
    ..003). CD20 expression thus appears to be associated with a worse outcome, which reinforces the interest of evaluating rituximab combined to chemotherapy in CD20-positive adult BCP-ALL. ClinicalTrials.gov ID, NCT00222027...
  74. ncbi A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL)
    Christiane Charrin
    Laboratoire d Hématologie et de Cytogénétique, Hopital Edouard Herriot, Place d Arsonval, 69437 Lyon Cedex 03, France
    Blood 104:2444-51. 2004
    ..We suggest that hypodiploidy with 30 to 39 chromosomes or near-triploidy should be regarded as a new high-risk factor in the risk stratification of adult ALL protocols...
  75. doi l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial
    Carine Domenech
    Institut d Hemato Oncologie pédiatrique, Hospices Civils de Lyon, Universite Claude Bernard, France
    Br J Haematol 153:58-65. 2011
    ..Other expected adverse events were comparable to those observed with E. colil-ASNase and there was also no difference between the three doses of GRASPA(®) ...
  76. doi Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study
    Francoise Huguet
    Department of Hematology, Hopital Purpan, Toulouse, France
    J Clin Oncol 27:911-8. 2009
    ....
  77. ncbi Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors
    D Revesz
    Leukemia Unit, Hematology Department, Edouard Herriot Hospital, 69437 Lyon Cedex 03, France
    Ann Hematol 82:684-90. 2003
    ..All other patients displayed a very poor outcome and must be oriented after failure of first-line therapy to alternate therapeutic programs based on investigational drugs...
  78. ncbi Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine
    Carlos Maria Galmarini
    Unité Inserm 590, Hopital Edouard Herriot, Lyon, France
    Br J Haematol 122:53-60. 2003
    ..Our results suggest that dCK and cN-II mRNA expression in leukaemic blasts at diagnosis is correlated with clinical outcome and may play a functional role in the resistance to ara-C in patients with AML...
  79. ncbi Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia
    C M Galmarini
    Unité INSERM 453 Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Lyon, France
    Blood 98:1922-6. 2001
    ..These results demonstrate that the expression of high levels of high Km 5NT in blast cells is correlated with outcome in patients with AML...
  80. ncbi Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia
    A De Labarthe
    Department of Hematology, Hopital Saint Louis, Paris, France
    Bone Marrow Transplant 35:767-73. 2005
    ..In NN patients, FLT3-ITD was the main bad-prognosis factor for second CR achievement and survival, leading to consider SCT earlier, at least in FLT3-ITD patients with a donor...
  81. ncbi Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features
    Christiane Charrin
    Laboratoire Central d Hématologie et de Cytogénétique, Hopital Edouard Herriot, Lyon, France
    Hematol J 3:21-31. 2002
    ....
  82. doi [Novel conventional therapies in onco-hemathology]
    Frederic Baleydier
    Institut d hématologie et oncologie pédiatrique, Hospices Civils de Lyon, France
    Bull Cancer 98:901-13. 2011
    ..The large field of monoclonal antibodies will be also approached focusing on antibodies developed in leukemias...
  83. doi Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole
    Mauricette Michallet
    Department of Hematology, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Med Mycol 49:681-7. 2011
    ..Patient's age and response to induction treatment are two independent infection risk factors, and need more attention during future clinical trials linked to antifungal prophylaxis...
  84. ncbi Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis
    A Thiebaut
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Ann Hematol 79:501-6. 2000
    ..This might suggest a benefit of initial leukapheresis in the treatment of AML presenting with hyperleukocytosis...
  85. ncbi Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials
    N Dhedin
    Department of Hematology, Hopital Pitie Salpetriere, Paris, France
    Leukemia 20:336-44. 2006
    ..Of interest, the reduced relapse risk after ASCT translated in better disease-free survival in the 300 rapid responders who reached CR after the first induction course...
  86. ncbi Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone
    E Voog
    , , Lyon, France
    Ann Hematol 80:584-91. 2001
    ..We conclude that PBSC mobilization with G-CSF alone initiated in steady state is a feasible, safe, and suitable procedure for harvesting cells in sight of autologous transplantation in adult acute myeloid leukemia...
  87. ncbi Influence of cigarette smoking on the presentation and course of acute myeloid leukemia
    Y Chelghoum
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon, France
    Ann Oncol 13:1621-7. 2002
    ....
  88. ncbi Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission
    E Tavernier
    Service d Hematologie Clinique, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    Indian J Cancer 40:140-3. 2003
    ..To our knowledge, this is the first description of a mini-allograft in an APL patient achieving molecular remission after As2O3 therapy...
  89. ncbi Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period
    X Thomas
    , , Lyon, France
    Leukemia 15:1811-22. 2001
    ..Only T cell lineage ALL outcomes have improved over the years. The results suggest a time (3 years) at which it becomes reasonable to speak of potential cure, provided the patient is in CR...
  90. ncbi Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome
    Roch Houot
    Service d Hematologie, Hopital Edouard Herriot, Lyon, France
    Hematology 9:369-76. 2004
    ..The very poor overall outcome in elderly patients with Ph+ ALL may be significantly improved by the introduction of imatinib mesylate into current treatment regimens...
  91. ncbi Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)
    A S Michallet
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon Cedex, France
    Bone Marrow Transplant 35:601-8. 2005
    ..A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation...
  92. ncbi Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study
    A Belhabri
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon, France
    Leuk Lymphoma 36:45-55. 1999
    ..5 months (range, 1-14 months) in the IDA and MIT arms respectively. We conclude that CBP at a cumulative dosage of 1 g/m2 together with intercalating agents (IDA/MIT) has antileukemic efficacy in elderly patients...
  93. ncbi Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission
    A Delannoy
    Department of Hematology, Hĵpital de Jolimont, Service d Hematologie, Haine Saint Paul, Belgium
    Leuk Lymphoma 43:75-81. 2002
    ..In conclusion, although similar to published studies in elderly patients with ALL, this study is inferior to our previous one. INF, given as a single drug, has a modest role if any in the treatment of older persons with ALL...
  94. ncbi Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases
    A Colita
    , Hĵpital Edouard Herriot, Lyon, France
    Ann Oncol 12:451-5. 2001
    ..Distinctive subgroups can be identified according to prognostic factors related to survival. A larger multicenter study with well-defined diagnostic criteria is warranted to further clarify treatment effects...
  95. doi Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases
    R Itzykson
    Service d Hematologie Clinique, Assistance Publique Hopitaux de Paris AP HP, Hôpital Avicenne Paris 13 University, Bobigny, France
    Leukemia 23:673-8. 2009
    ..EPO-beta-ATRA combination appears a possible therapeutic option in anemia of MDS having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve neutropenia and thrombocytopenia...
  96. doi Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association
    Aline Renneville
    Department of Hematology, University of Lille Medical School, Lille, France
    Cancer 115:3719-27. 2009
    ..Recently, 2 groups reported that WT1 mutations occur in approximately 10% of normal karyotype AMLs and are an independent predictor of poor outcome in this subgroup of patients with AML...
  97. ncbi Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure
    Thomas Benet
    Department of Hygiene, Epidemiology, and Prevention, Hopital Edouard Herriot, Hospices Civils de Lyon, France
    Clin Infect Dis 45:682-6. 2007
    ..The objective of the study was to assess the impact of the relocation of an adult hematological intensive care unit on invasive aspergillosis (IA) incidence...
  98. ncbi Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: Dominant role for TNFbeta, in concert with IFNgamma
    A Eljaafari
    Cell Therapy Research Department, EFS Rhone Alpes, Lyon, France
    Leukemia 20:1992-2001. 2006
    ..In conclusion, we show herein that upon allogeneic reaction, TNFbeta secretion contributes, in concert with IFNgamma, to increase or restore surface molecules involved in AML blast interaction with T cells...
  99. ncbi Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group
    C Callens
    Department of Hematology, Hopital Saint Louis, Paris, France
    Leukemia 19:1153-60. 2005
    ....
  100. ncbi Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia
    Sandrine Hayette
    Blood 99:4647-9. 2002